About Laura Spring, MD

Dr. Spring is a clinical/translational investigator and breast medical oncologist at the Massachusetts General Hospital Cancer Center and Harvard Medical School.  She is board certified in internal medicine and medical oncology. Dr. Spring completed residency training at Brigham & Women's Hospital and her medical oncology training through the Dana-Farber/Partners Cancer Care Oncology Fellowship Program.

The primary focus of her research is to develop novel therapeutic and biomarker strategies to improve the care of breast cancer patients. She is particularly interested in blood-based monitoring of localized breast cancer and the use of targeted therapies in the neoadjuvant setting. Dr. Spring is involved with the design and conduct of several breast cancer clinical trials for localized and metastatic breast cancer.

Departments, Centers, & Programs:

Treats:

Locations

Hematology/Oncology
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-726-6500
Phone: 617-724-4000
Fax: 617-724-1079

Medical Education

  • MD, University of Massachusetts Medical School
  • Residency, Brigham and Women's Hospital
  • Fellowship, Dana Farber Cancer Institute

American Board Certifications

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Spring is a clinical/translational investigator and breast medical oncologist at the Massachusetts General Hospital Cancer Center and Harvard Medical School. The primary focus of her research is to develop novel therapeutic and biomarker strategies to improve the care of breast cancer patients. She is particularly interested in blood-based monitoring of localized breast cancer and the use of targeted therapies in the neoadjuvant setting. Dr. Spring is involved with the design and conduct of several breast cancer clinical trials for localized and metastatic breast cancer.